Aeolus Pharmaceuticals to Present at OneMed Forum SF 2015 Conference
30 déc. 2014 08h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 30, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Fiscal Year 2014 Financial Results
22 déc. 2014 17h16 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 22, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Files International Patent Application for New Patent on AEOL 10150
03 déc. 2014 08h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 03, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)Filing covers synthesis, formulation and pharmaceutical compositionCould significantly increase term of...
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
02 déc. 2014 11h31 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 02, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Presentation of Efficacy Data for AEOL 10150 in Multiple Studies Showing Significant Survival Improvement and Tissue Protection After Radiation Exposure to the Lungs
20 oct. 2014 07h00 HE
|
Aeolus Pharmaceuticals, Inc.
MISSION VIEJO, CA--(Marketwired - October 20, 2014) - • Data Reported in Presentation and Posters at the 60th Annual Meeting of the Radiation Research SocietyAeolus Pharmaceuticals, Inc.
(OTCQB: AOLS)...
Aeolus Announces Positive Results From Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
04 sept. 2014 07h00 HE
|
Aeolus Pharmaceuticals, Inc.
MISSION VIEJO, CA--(Marketwired - September 04, 2014) - Findings reported by Dr. Tom MacVittie of the University of Maryland School of Medicine will be included in a pre-Emergency Use Authorization...
Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
20 août 2014 13h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 20, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of...
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
15 août 2014 07h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas
01 juil. 2014 07h30 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 1, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data Presented at 8th Annual NIH Counteract Meeting in Denver
...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure
18 juin 2014 10h39 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 18, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced the publication of data from animal model studies demonstrating the efficacy of...